A r t i c l e s
The HIV type 1 (HIV-1) epidemic continues to spread at the alarming rate of ~2.5 million new cases per year, and a safe and effective HIV vaccine is still elusive. Currently used strategies to fight the spread of HIV-1 include pre-exposure prophylaxis using small-molecule antiretroviral drugs [1] [2] [3] and virus-inhibiting immunoglobulins 4 . However, compared to antiviral drugs, HIV-1-neutralizing antibodies tend to have better in vivo pharmacokinetic profiles in humans. HIV-1-neutralizing antibodies have shown efficacy in several animal models. For example, passive administration of monoclonal antibodies (mAbs) specific for the envelope proteins gp120 or gp41 (these mAbs include b12, 2G12, 2F5 and 4E10) protects rhesus macaques against challenge with simian-human immunodeficiency virus (SHIV) 5, 6 . However, mAb-based passive immunization therapy was considered infeasible for a long time due to the relatively weak potency and/or narrow breadth of the available HIV-1-neutralizing mAbs. However, recently identified human anti-HIV mAbs including VRC01 (ref. 7) , PG9 (ref. 8) , 3BNC117 (ref. 9) , PGT antibodies 10, 11 , NIH45-46G54W 12 and 10E8 (ref. 13 ) with much greater breadth and potency increase enthusiasm about the prospect of using mAbs for pre-exposure prophylaxis or passive immunization. Indeed, compared to first-generation HIV-1-neutralizing mAbs, much lower concentrations of one such next-generation antibody protected monkeys from virus challenge 11 . In addition, adeno-associated virus-based expression of VRC01 in a humanized mouse model led to successful prophylaxis against HIV-1 infection 14 . Nevertheless, with the exception of 10E8, most of these next-generation mAbs neutralize only ~70-90% of circulating HIV-1 strains, even at concentrations as high as 50 µg/ml.
Pre-exposure prophylaxis strategies may also use mAbs specific for the HIV-1 receptors CCR5 (ref. 15 ) and CD4 (refs. 16-19) , as such mAbs also show potent and broad inhibitory activity against HIV-1. For example, ibalizumab (formerly TNX-355) is a humanized IgG4 mAb that blocks HIV-1 entry by binding to human CD4 with high affinity [17] [18] [19] [20] [21] . Ibalizumab inhibits entry of a diverse spectrum of clinical and laboratory-adapted HIV-1 isolates, including CCR5-tropic and CXCR4-tropic strains from multiple subtypes. Mutagenesis 22 and structural studies 23 demonstrated that ibalizumab binds CD4 mainly by direct contacts with the BC-loop (AA 121-125) in domain 2 (D2) of CD4. Additional contacts include those between residues 164 and 165 (the short FG loop in D2) of CD4 and the ibalizumab heavy (H) chain, as well as between the Ser79 and Glu77 (in the EF loop in D1) of CD4 and the ibalizumab light (L) chain. Located at the interface between D1 and D2 of CD4, the ibalizumab epitope is positioned on the opposite side from the region of CD4 that engages HIV-1 gp120 or major histocompatibility complex class II (Fig. 1) . Consistent with these findings, ibalizumab does not inhibit binding of CD4 to monomeric gp120 (ref. 16 ). Thus, ibalizumab is thought to inhibit a post-HIV-1 attachment step required for virus entry. In phase 1, phase 2a and phase 2b clinical trials in HIV-1 patients, ibalizumab treatment resulted in substantial reductions (~1 log) in viral load and significant increases in CD4 + T-cell counts, without serious immunologic impairments or adverse effects 17, 19 . We are now planning a phase 3 clinical trial to examine ibalizumab's efficacy in HIV-1 patients with multidrug-resistant viruses in need of salvage antiretroviral therapy. We are also exploring the feasibility of using ibalizumab and ibalizumab variants for the purpose of HIV-1 prevention.
Unfortunately, HIV-1 strains with reduced susceptibility to ibalizumab (in terms of ibalizumab effects on virus infectivity) were isolated from HIV-1 patients who experienced a rebound in viral load after the addition of ibalizumab to failing antiretroviral drug regimens 24 . In most of these cases, a much reduced plateau of maximum percentage of inhibition (MPI) in the dose-response curve was observed 17, 24 . In other words, complete virus inhibition cannot be strategic addition of an N-linked glycan to a monoclonal antibody improves its HiV-1-neutralizing activity Ibalizumab is a humanized monoclonal antibody that binds human CD4-a key receptor for HIV-and blocks HIV-1 infection. However, HIV-1 strains with mutations resulting in loss of an N-linked glycan from the V5 loop of the envelope glycoprotein gp120 are resistant to ibalizumab. Previous structural analysis suggests that this glycan fills a void between the gp120 V5 loop and the ibalizumab light chain, perhaps causing steric hindrance that disrupts viral entry. If this void contributes to HIV-1 resistance to ibalizumab, we reasoned that 'refilling' it by engineering an N-linked glycan into the ibalizumab light chain at a position spatially proximal to gp120 V5 may restore susceptibility to ibalizumab. Indeed, one such ibalizumab variant neutralized 100% of 118 diverse HIV-1 strains tested in vitro, including 10 strains resistant to parental ibalizumab. These findings demonstrate that the strategic placement of a glycan in the variable region of a monoclonal antibody can substantially enhance its activity.
1 0 4 8 VOLUME 31 NUMBER 11 NOVEMBER 2013 nature biotechnology A r t i c l e s achieved despite increasing antibody concentrations. Such flattening of the virus-inhibition curve is characteristic of the resistance profile for a noncompetitive inhibitor of HIV-1 entry. Further evaluation of ibalizumab-resistant viruses indicated that reduced susceptibility to ibalizumab is conferred by the loss of one or two potential N-linked glycosylation sites (PNGS) in the V5 loop of HIV-1 gp120 (ref. 24) . Indeed, among wild-type (WT) HIV-1 isolates, there is a strong correlation between the number of V5 glycosylation sites and ibalizumab susceptibility 25 . Moreover, site-directed mutagenesis confirmed that the loss of glycan at the V5 N terminus was the major contributor to ibalizumab resistance 25 .
We propose, based on structural modeling, that a glycan on the N terminus of gp120 fills a vacant space between the L chain of ibalizumab and gp120 V5, and that ibalizumab's effect on HIV-1 entry is sterically mediated by the mass effect of this glycan. We confirmed this hypothesis by creating a panel of ibalizumab mutants with potential N-linked glycosylation sites at various positions in the L chain and measuring their ability to neutralize HIV-1 infectivity in vitro. Indeed, ibalizumab mutants bearing a glycan located in close proximity to V5 in the ibalizumab-CD4-gp120 complex efficiently neutralized HIV-1. These ibalizumab mutants also neutralized HIV-1 strains that were resistant to WT ibalizumab. One particular ibalizumab mutant, LM52, neutralized 100% of the tested 118 HIV-1 isolates at a potency more than tenfold higher than WT ibalizumab, judging by the geometric mean IC 80 , the antibody concentration required to neutralize 80% of infection. The results of this study suggest that ibalizumab blocks HIV-1 entry through a steric hindrance mechanism, and they provide an example of how strategic placement of an N-linked glycosylation site can be used to improve the activity of a mAb. In addition, to our knowledge, there is no previous report of a monospecific mAb of natural architecture reported to neutralize the infectivity of 100% of the HIV-1 strains tested.
RESULTS

Design of ibalizumab variants
Studies of ibalizumab-resistant HIV-1 strains have revealed that resistance is mainly conferred by the loss of glycan(s) from the V5 loop of HIV-1 envelope (Env) gp120 (refs. 24,25) . To further explore the role of V5 glycosylation in ibalizumab susceptibility, we modeled the interactions between gp120, CD4 and ibalizumab using the structures reported to the Protein Data Bank (accession number 2NXY and 3O2D). The V5 N-terminal glycan is situated closest to the ibalizumab L chain (Fig. 1a) , whereas the V5 C-terminal glycan is further away from ibalizumab (Fig. 1b) . This model raises the possibility that the fit of the N-terminal glycan into the space between gp120 and ibalizumab exerts a mass effect on gp120, thereby disrupting its conformational changes (twists and turns) that are essential for HIV-1 entry into the target cell. This model also suggests that introduction of a similarly sized glycan into the ibalizumab L chain may boost its ability to inhibit entry of HIV-1 strains that have lost their V5 N-terminal glycan.
We therefore introduced potential N-linked glycosylation sites into residues (30E, 52, 53, 54, 60, 65, 67 and 76) in the variable region of the ibalizumab L chain that are proximal to the V5 loop of gp120. These ibalizumab L-chain mutants were constructed, sequenced and used to transfect 293A cells to produce mutant proteins. We purified the variant mAbs by protein-A agarose chromatography and analyzed them by SDS-PAGE (Fig. 2a) . Yields of L-chain mutants from transient expression in 293A cells were comparable to those of WT ibalizumab (data not shown). In each of the L-chain mutants, the L chain was slightly bigger than the WT L chain. To confirm that the larger L chains were due to glycosylation, we treated L-chain mutants 30E, 52 and 53 with peptide N-glycosidase (PNGase) F under denaturing conditions and analyzed them by SDS-PAGE (Fig. 2b) . As expected, the L chains of these variants after PNGase F treatment were reduced to the size of the WT L chains. We next used mass spectrometry to identify the form of N-linked glycans introduced to the L chain of LM52 and routinely produced in 293A cells. Over six forms of complex type N-glycans with 8-12 rings were identified on the L chain, with 80% of these forms having 9-11 rings (Fig. 2c) . Taken together, these data confirmed that N-linked glycans were introduced into the desired residues of the ibalizumab L chain.
CD4 binding and HIV-1 neutralization by L-chain mutants
We next evaluated the kinetics of the binding of these ibalizumab L-chain mutants to human soluble CD4 (sCD4) by surface plasmon resonance. In a Biacore assay using sCD4 as the analyte, WT ibalizumab and L-chain mutants bound sCD4 with similar binding kinetics. The K D of six of these L-chain mutants bound to sCD4 was in the range of 0.19-0.8 nM (Supplementary Table 1) , and these numbers were within twofold of the K D of WT ibalizumab (0.43 nM). These data showed that the addition of an N-linked glycan at these select locations in the L chain of ibalizumab did not markedly affect the mAb's ability to bind CD4.
We next explored the HIV-1-neutralizing capacity of the L-chain mutants compared to that of WT ibalizumab. To this end, we tested the L-chain mutants against a panel of HIV-1 viruses that were resistant or partially resistant to ibalizumab, including three replication-competent HIV-1 strains (Fig. 3) . Using this panel of ibalizumabresistant viruses, an average MPI of 75% and IC 80 of 0.87 µg/ml were observed when WT ibalizumab was tested at concentrations up to 2 µg/ml. Markedly improved neutralization activities were observed for four L-chain mutants (LM30E, LM52, LM53 and LM67), with an average MPI of 91-99% and IC 80 of 0.05-0.14 µg/ml (Fig. 3 and Supplementary Table 2 ). Among these, LM52 appeared to have the best HIV-1 neutralization potency. Two other variants (LM54 and LM65) yielded more modest improvement in virus-neutralization activities compared to ibalizumab. Interestingly, the potential Nlinked glycosylation sites in the six L-chain mutants that showed improved HIV-1 neutralizing activity were also closer to V5 (459) Figure 1 Model of glycosylation in V5 of HIV-1 gp120, in the context of both CD4 and ibalizumab (using PyMOL). The complex was modeled by superimposing the structure of D1 and D2 of CD4 in complex with gp120 (Protein Data Bank (PDB) accession number 2NXY) onto the same domains of CD4 in complex with ibalizumab (PDB 3O2D). The glycan (dark blue) was introduced at the relevant asparagine by superimposing the asparagine with that of a glycan-bound asparagine from PDB 3TYG. The H and L chains of ibalizumab are shown as cyan and magenta ribbons, respectively. The first two domains of human CD4 are green, whereas HIV-1 gp120 is orange/brown. A Table 2 and Supplementary Fig. 1 ) than the potential N-linked glycosylation sites in LM60 and LM76, which showed HIV-1 neutralizing activity comparable to that of WT ibalizumab. Therefore, it seems that positioning the N-glycan closer to V5 improves the neutralization profile of ibalizumab variants. We note, however, that the orientation of the glycan, in addition to the distance to V5, may also play a critical role.
Glycan size influences LM52 activity
We next studied whether glycan size influences the improved HIV-1 neutralization activity of the L-chain mutants. We focused on LM52 because of its superior HIV-1 neutralization profile (Fig. 3) . To produce a version of LM52 lacking any N-linked glycan, we added tunicamycin 26 , which inhibits N-acetylglucosamine (GlcNAc) phosphotransferase, to 293A cells immediately after transient transfection with the LM52 construct. Similarly, to produce a version of LM52 tagged with glycans of 10 or 11 rings (the high mannose (Man)-type N-glycan Man 8 GlcNAc 2 (Man8) or Man 9 GlcNAc 2 (Man9)), we added kifunensine 27 , which inhibits mannosidase I, to 293A cells. Lastly, to produce a version of LM52 bearing a 7-ring glycan (high mannose (Man)-type N-glycan Man 5 GlcNAc 2 (Man5)), we used N-acetylglucosaminyltransferase I-negative GnT1(−) HEK293S cells 28 . As shown by SDS-PAGE, although the addition of kifunensine did not noticeably change the size of the L chain, addition of tunicamycin or growth in GnT1(−) cells noticeably reduced the size of the L chain (Fig. 4a) . Similarly, the neutralization activities against three HIV-1 strains were more severely reduced for antibodies produced in the presence of tunicamycin or in GnT1(−) cells than for the antibody produced in the presence of kifunensine (Fig. 4b) . Thus, stronger HIV-1-neutralizing activity was observed when larger glycans were present in the L chain at residue 52. Modeling suggests that larger glycans better fill the space between the L chain and gp120 (Fig. 4c) , but the nature of the branching of the glycan may also affect the HIV-1 neutralizing activity of LM52.
Neutralization breadth and potency of LM52
We then tested the HIV-1 neutralization activity of LM52 against a panel of 118 diverse HIV-1 viral strains covering 11 clades. LM52 showed markedly improved neutralization breadth and potency compared to WT ibalizumab in this single-cycle TZM-bl assay ( Fig. 5 and Supplementary Table 3) . LM52 had no neutralizing activity against the negative control virus (murine leukemia virus) (Supplementary Table 3 ), but it neutralized (as defined by ≥50% inhibition) all HIV-1 strains tested, whereas WT ibalizumab neutralized 92%. In fact, LM52 neutralized 97% of viruses to ≥95% inhibition, compared to WT ibalizumab's 31% (Fig. 5, upper A r t i c l e s for WT ibalizumab (Fig. 5, middle panels) . Indeed, all of the viruses were neutralized by LM52 with an IC 80 < 0.3 µg/ml, whereas 36% of the viruses were not 80% neutralized by WT ibalizumab even at a concentration of 10 µg/ml (Fig. 5, lower panels) .
Overall, the geometric mean IC 50 value for LM52 was 14 ng/ml, compared to 74 ng/ml for WT ibalizumab, and the geometric mean IC 80 value for LM52 was 37 ng/ml, compared to 510 ng/ml for WT ibalizumab (Supplementary Fig. 2 ). When the viruses were separated into ibalizumab-sensitive (MPI > 80%) and ibalizumab-resistant strains (MPI ≤ 80%), it was evident that the enhanced potency of LM52 was most obvious in ibalizumab-resistant viruses ( Supplementary  Fig. 3) . In ibalizumab-resistant viruses, the geometric mean IC 80 value for LM52 was 50 ng/ml, compared to almost 10,000 ng/ml for WT ibalizumab. The potency of LM52 was enhanced by about threefold even in ibalizumab-sensitive viruses.
The improved activity of LM52 was also evident in a plot comparing its HIV-1 strain coverage across increasing antibody concentrations (Fig. 6) . The improvement over WT ibalizumab was readily apparent, as was its superiority over mAbs (PG9, VRC01, 10E8 and NIH45-46G54W) known for their broad and potent HIV-1 neutralizing activity. LM52 had the greatest viral coverage at all concentrations >0.01 µg/ml and it reached 100% at <0.1 µg/ml. Only at concentrations <0.01 µg/ml was LM52 coverage inferior to that of NIH45-46G54W 12 , a modified version of a human mAb directed to the CD4-binding site on gp120. It should be noted, however, that ibalizumab inhibits HIV-1 infection by binding to CD4, whereas VRC01, PG9, 10E8 and NIH45-46 G54W inhibit HIV-1 infection by binding directly to the virus. Nonetheless, regardless of whether these mAbs bind viral envelope or CD4, they all neutralize HIV-1 infection by blocking viral entry.
Effects of multiple glycans
We next examined the effect of placing two or three glycans in the region of interest in the ibalizumab L chain. We produced LM30E-52, LM30E-53 and LM52-67 double mutants, as well as LM30E-52-67 and LM30E-53-67 triple mutants in 293A cells and then purified and analyzed the antibodies by SDS-PAGE (Supplementary Fig. 4a ). Compared to WT ibalizumab or single-mutant L-chain mutants, a slightly bigger L chain was observed in each of the double mutants, and an even bigger L chain was observed in each of the triple mutants. We next explored the (c) Depiction (using PyMOL) of the space filled by glycans of representative conformations and sizes, when tagged on residue 52 of ibalizumab. Depiction is based on the model generated in Figure 1 and colors are the same. The 7-ring N-glycan, Man 5 GlcNac 2 , was extracted from PDB entry 3TYG. An 11-ring N-glycan, Man 3 GlcNac 5 Fuc, was extracted from PDB entry 3QUM. These results represent three independent experiments. npg HIV-1 neutralization profile of these variant mAbs against a panel of HIV-1 strains known to be fully or partially resistant to ibalizumab. In general, the double and triple mutants showed neutralizing activity comparable to that of LM52 (Supplementary Table 4 and Supplementary Fig. 4b, left panel) . In fact, the geometric mean IC 80 values suggest that the triple mutants may be slightly less potent compared to LM52. The only exception noted was for SHIVsf162P3N, a virus more sensitive to the double and triple mutants than to LM52 (Supplementary Table 4 and Supplementary Fig. 4b, right panel) . Overall, we found no evidence that adding more than one glycan further improves the HIV-1 neutralization profile of LM52 against LM52-sensitive viruses. The improvement to LM52 by the addition of a second glycan may only be apparent with viruses resistant or partially resistant to LM52.
Analysis of LM52 polyreactivity
A property common to some HIV-1-neutralizing mAbs is their crossreactivity with self-antigens 29, 30 . Neither LM52 nor ibalizumab bound to HEp-2 epithelial cell extracts (Supplementary Fig. 5a ), even at concentrations of 10 µg/ml. In addition, neither LM52 nor ibalizumab showed reactivity with single-stranded DNA, double-stranded DNA, insulin, lipopolysaccharide or keyhole limpet hemocyanin (Supplementary Fig. 5b ). Human CD4 protein, the intended target of ibalizumab, was the only self-antigen tested that was recognized by LM52. Thus, we find no evidence that LM52 is polyreactive with self-antigens.
DISCUSSION
We have created an HIV-1 entry-blocking mAb product in the ibalizumab variant LM52, which at relatively low concentrations neutralized all HIV-1 strains tested. To our knowledge, no previous study has reported a mAb demonstrating 100% viral coverage against a large panel of HIV-1 isolates. However, two bi-specific antibodies have been recently reported to possess inhibitory activity against all HIV-1 strains tested 31 . The virus-neutralizing properties of LM52 are also evidently superior to those of the WT ibalizumab as well as of a number of the best anti-Env mAbs reported to date, for example, VRC01 (ref. Together with the established safety record of the parental ibalizumab in humans, these observations suggest that LM52 may be a good candidate for clinical development for the treatment or prevention of HIV-1. This modified antibody may be particularly suitable as a long-acting, pre-exposure prophylaxis agent given its expected (based on the known pharmacokinetic properties of the parental ibalizumab) schedule of monthly administration. These findings also provide insight into the mechanism of action of ibalizumab. That HIV-1 loses a glycan in the N terminus of gp120 V5 to become resistant to ibalizumab 24, 25 already suggested the possibility that the ibalizumab mechanism of action is mediated by the glycan resulting in a steric clash between the antibody L chain and the viral envelope glycoprotein, thereby sterically disrupting a step in HIV-1 entry. Our observations indicating that a glycan on the L chain restores the antiviral activity of ibalizumab against ibalizumabresistant strains, that positioning this glycan on key residues spatially closest to V5 resulted in the greatest antiviral effect, and that larger glycans conferred larger effects on virus neutralization collectively support, but do not prove, that ibalizumab blocks HIV-1 infection by means of a steric hindrance mechanism.
This study also expands our knowledge about the influence of glycosylation on antibody activity. Under normal circumstances, an N-linked glycosylation site exists at amino acid 297 in the H chain of all IgG subclasses 32, 33 . The effect of this glycan has been studied extensively and found to be essential in mediating proinflammatory activity by maintaining the H chain in an open conformation required for FcγR binding. It has also been noted that Fc molecules with fucosylated and sialylated glycans have reduced affinities for FcRs compared with afucosylated or asialylated Fc molecules 32, 34 . In addition, ~20% of human IgGs have potential N-linked glycosylation site motifs within the variable region 34 , but the role of N-linked glycans in this region has not been thoroughly investigated. Although two studies reported that the introduction of an N-linked carbohydrate in the variable region resulted in improved solubility 35, 36 , no previous study has shown that a glycan strategically placed in the variable region of an antibody markedly improves its activity. mAbs have become a major class of drugs in our therapeutic arsenal, particularly for cancers and autoimmune disorders. Whereas some antibody drugs mediate their clinical effect by acting as competitive inhibitors, others act by steric hindrance. For select mAbs in the latter category, the glycan-addition approach described herein may be adapted to enhance their functional activity. It is conceivable that increasing the bulk at key positions on the antibody, when structural information on the antigen-antibody complex is available, could lead to better activity. Our study provides an example of how a structuralactivity relationship could be exploited to generate a superior mAb product. It also demonstrates the power of using such relationships to develop improved biological products, as chemists have done for small-molecule drugs for decades.
METHODS
Methods and any associated references are available in the online version of the paper. Figure 6 HIV-1 strain coverage of LM52. Viral coverage of WT ibalizumab, LM52 and PG9, 10E8, VRC01 and NIH45-46G54W HIV-1 broadly neutralizing antibodies. LM52 and ibalizumab were tested at up to 10 µg/ml, whereas the other mAbs were tested at up to 50 µg/ml. The data for PG9, 10E8, VRC01 and NIH45-46G54W were obtained from the published literature 7, 8, 12, 13 or newly generated by M.S.S.
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